Adam Rafi
Interventional Cardiology · Quincy, ILNPI 1356640825
Payments from drug & device makers
Across 719 payments — averaging $116.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$73K
- Boston Scientific$2K
- Abbott$2K
- Johnson & Johnson$1K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$778
- plus $4K from 24 others
What the payments were for
- Travel & lodging$2,54223%
- Food & beverage$8,52577%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 252 | $72,853 |
| Boston Scientific | 24 | $2,376 |
| Abbott | 23 | $1,567 |
| Johnson & Johnson | 69 | $1,278 |
| Novartis | 84 | $1,070 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 65 | $778 |
| Amgen | 26 | $423 |
| Merck | 24 | $419 |
| Medtronic(2 entities) | 13 | $415 |
| E.r. Squibb & Sons, L.L.C. | 20 | $401 |
| Preventric Diagnostics, Inc. | 1 | $384 |
| Pfizer | 24 | $362 |
| Boehringer Ingelheim | 14 | $249 |
| Actelion Pharmaceuticals US, Inc. | 13 | $207 |
| AstraZeneca | 13 | $190 |
| Shockwave Medical, Inc | 8 | $174 |
| Sanofi-aventis U.S. LLC | 10 | $168 |
| Amarin Pharma, Inc. | 13 | $157 |
| Biotronik Inc. | 8 | $137 |
| Philips North America LLC | 3 | $132 |
| Recor Medical Inc | 2 | $44 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Inari Medical, Inc. | 1 | $23 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,959 in reported general payments places this provider in the 80th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 425 | $430,162 |
| EliquisApixaban | 323 | $250,876 |
| EntrestoSacubitril/Valsartan | 170 | $177,223 |
| MultaqDronedarone Hcl | 39 | $49,865 |
| JardianceEmpagliflozin | 45 | $45,037 |
| Repatha SureclickEvolocumab | 66 | $44,102 |
| BrilintaTicagrelor | 73 | $39,321 |
| FarxigaDapagliflozin Propanediol | 50 | $36,125 |
| VascepaIcosapent Ethyl | 24 | $12,588 |
| Metoprolol Succinate | 959 | $8,518 |
| Nifedipine ErNifedipine | 343 | $8,151 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $7,642 |
| Atorvastatin Calcium | 1,056 | $7,176 |
| Ranolazine ErRanolazine | 100 | $6,994 |
| Praluent PenAlirocumab | 13 | $6,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,278 | $430,162425 claims |
| PfizerEliquis | $362 | $250,876323 claims |
| NovartisEntresto | $1,070 | $177,223170 claims |
| AstraZenecaBrilinta, Farxiga | $190 | $75,446123 claims |
| Sanofi-aventis U.S. LLCMultaq | $168 | $49,86539 claims |
| Boehringer IngelheimJardiance | $249 | $45,03745 claims |
| Esperion Therapeutics, Inc.Nexlizet | $13 | $7,64213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Quincy
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Sunil AgarwalSpringfield$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.